Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

This study investigates how exenatide — an FDA-approved blood sugar medication used in non-pregnant type 2 diabetes patients — works in pregnant women with gestational diabetes. Researchers want to understand how quickly the body processes exenatide and how effectively it helps control blood sugar after meals, since current options (insulin and glyburide) don't work well for all women. Eligible participants are pregnant women aged 18–50 with gestational diabetes not yet requiring medication, who are carrying a single baby and have no history of blood sugar treatment or significant gastrointestinal, kidney, or pancreatic conditions. Participation involves pharmacokinetic and pharmacodynamic testing to measure how the drug moves through the body and affects insulin secretion. This summary was prepared as patient-facing educational content using AI assistance.